Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prescription Status For Pseudoephedrine In U.K. Put On Hold For Two Years

This article was originally published in The Tan Sheet

Executive Summary

The British health authority will move pseudoephedrine- and ephedrine-containing OTCs to prescription-only status in two years unless the risk of the products' use in the illicit manufacturing of methamphetamine decreases by that time

You may also be interested in...



U.K. Industry Asks For More Time To Prepare For Limits On OTC PSE Sales

U.K. drug firms say the country's regulatory agency is not allowing enough time to comply with an order banning nonprescription access to product packages with more than 720 mg of pseudoephedrine beginning April 1

U.K. Industry Asks For More Time To Prepare For Limits On OTC PSE Sales

U.K. drug firms say the country's regulatory agency is not allowing enough time to comply with an order banning nonprescription access to product packages with more than 720 mg of pseudoephedrine beginning April 1

U.K. Industry Asks For More Time To Prepare For Limits On OTC PSE Sales

U.K. drug firms say the country's regulatory agency is not allowing enough time to comply with an order banning nonprescription access to product packages with more than 720 mg of pseudoephedrine beginning April 1

Related Content

Topics

UsernamePublicRestriction

Register

PS100867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel